S
Susan G. Arbuck
Researcher at National Institutes of Health
Publications - 47
Citations - 5047
Susan G. Arbuck is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Aminocamptothecin & Paclitaxel. The author has an hindex of 25, co-authored 47 publications receiving 4898 citations. Previous affiliations of Susan G. Arbuck include Case Western Reserve University.
Papers
More filters
Journal ArticleDOI
Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials.
J. I. Johnson,S. Decker,Daniel W. Zaharevitz,Larry Rubinstein,J M Venditti,S Schepartz,S Kalyandrug,Michaele C. Christian,Susan G. Arbuck,Melinda G. Hollingshead,Edward A. Sausville +10 more
TL;DR: For 39 agents with both xenograft data and Phase II clinical trials results available, in vivo activity in a particular histology in a tumour model did not closely correlate with activity in the same human cancer histology, casting doubt on the correspondence of the pre-clinical models to clinical results.
Journal ArticleDOI
Accelerated Titration Designs for Phase I Clinical Trials in Oncology
Richard M. Simon,Boris Freidlin,Larry Rubinstein,Susan G. Arbuck,Jerry M. Collins,Michaele C. Christian +5 more
TL;DR: Accelerated titration (i.e., rapid intrapatient drug dose escalation) designs appear to effectively reduce the number of patients who are under-treated, speed the completion of phase I trials, and provide a substantial increase in the information obtained.
Journal ArticleDOI
Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.
Adrian M. Senderowicz,Donna Headlee,S.F. Stinson,Richard Lush,N Kalil,L. Villalba,K. Hill,Seth M. Steinberg,William D. Figg,Anne Tompkins,Susan G. Arbuck,Edward A. Sausville +11 more
TL;DR: The maximum-tolerated dose (MTD) of infusional flavopiridol is 50 mg/m2/d x 3 with dose-limiting secretory diarrhea, based on chronic tolerability, which is the recommended phase II dose without ADP.
Journal ArticleDOI
Clinical Trial Designs for Cytostatic Agents: Are New Approaches Needed?
Edward L. Korn,Susan G. Arbuck,James M. Pluda,Richard M. Simon,Richard Kaplan,Michaele C. Christian +5 more
TL;DR: Options for modifying trial designs to accommodate cytostatic agents are discussed and examples are given where these options have been tried or are currently being tried.
Journal ArticleDOI
Phase I Trial of 72-Hour Continuous Infusion UCN-01 in Patients With Refractory Neoplasms
Edward A. Sausville,Susan G. Arbuck,Richard A. Messmann,Donna Headlee,Kenneth S. Bauer,Richard Lush,Anthony J. Murgo,William D. Figg,Tyler Lahusen,Susan Jaken,Xiu-xian Jing,Michel Roberge,Eiichi Fuse,Takashi Kuwabara,Adrian M. Senderowicz +14 more
TL;DR: Preliminary evidence suggests UCN-01 modulation of both PKC substrate phosphorylation and the DNA damage-related G(2) checkpoint may be responsible for disease stability in refractory neoplasms.